Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 793, Issue -, Pages 119-126Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2016.11.018
Keywords
Corilagin; Schistosomiasis; Liver fibrosis; M2 macrophage; IL-13
Categories
Funding
- National Natural Science Foundation of China [81371840]
Ask authors/readers for more resources
This study tried to find the mechanism of Corilagin interference with interleukin (IL)-13/signal transducer and activator of transcription (STAT) 6 signaling pathways in IL-13-activated liver alternative activation macrophages in schistosomiasis-induced liver fibrosis in Balb/c mice. As a result, IL-13 in serum and the mRNA expression of IL-13 Receptor alpha 1, IL-4 Receptor a and downstream mediators supressor of cytokine signaling (SOCS) 1, Kruppel-like factor (KLF) 4, peroxisome proliferator-activated receptor (PPAR) delta in the liver tissue were significantly inhibited by Corilagin (P < 0.05 or 0.01). The protein expression of IL-13 Receptor al, IL-4 Receptor alpha, SOCS1, KLF4, PPAR gamma, PPAR delta and Phospho-STAT6 (P-STAT6) in Corilagin group were also markedly suppressed when compared with the model group (P < 0.05 or 0.01). Furthermore, the inhibitory effect was enhanced when the concentration of Corilagin increased (P < 0.05). By hematoxylin and eosin (HE) staining, when compared with the model group, the Corilagin group showed smaller granulomas (P < 0.05 or 0.01). The area of positive cells and integrated optical density (IOD) of CD68, CD206 and KLF4 was significantly decreased by Corilagin stained by IHC (P < 0.05 or 0.01). In conclusion, Corilagin had potential to relieve hepatic fibrosis caused by egg granuloma in Schistosoma japonicum infection by decreasing the expression of molecules associated with IL-13/STAT6 signaling pathway in liver alternative activation macrophages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available